Wouldn’t a new drug be better than an old one?Actually, for RAC...

Wouldn’t a new drug be better than an old one?

Actually, for RAC shareholders, Zantrene’s history is a huge advantage. When brand new molecules are developed to target a new approach in therapy, those drugs have to prove their safety and efficacy in preclinical studies, then in clinical trials. This process can take over a decade. Zantrene’s advantage here comes from the time it has already spent in the clinic. Having been in over 40 trials and more than 2000 patients, Zantrene’s safety and tolerability are already well understood. This massively de-risks RAC as a biotech investment and gives it a huge, multi-year head start on competitors looking to develop their own FTO inhibitor from scratch. Dr Tillet gave some further insight in this post.